Related and Nonrelated Parties [Axis] Related Party [Member] Nonrelated Party [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Investment, Name [Axis] GMP Biotechnology Limited [Member] Dragon Overseas Capital Limited [Member] Legal Entity [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Securities Purchase Agreements [Member] Title and Position [Axis] May 2022 Note and July 2025 Note [Member] JV [Member] May 2022 Note [Member] Equity Purchase Agreement [Member] Independent Contractor Agreement [Member] JH Darbie Placement Agreement [Member] Accredited Investors [Member] Securities Purchase Agreement and Purchase Agreement [Member] Golden Mountain Partners [Member] Since Inception Date [Member] Point R merger agreement [Member] Mast Hill [Member] Financial Instrument [Axis] Lunai Bioworks, Inc [Member] Lunai [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Point R Merger [Member] Antidilutive Securities [Axis] Convertible Debt Securities [Member] Consolidated Entities [Axis] Consolidated Entity, Excluding Consolidated VIE [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Measurement Input Type [Axis] Measurement Input Revenue Growth Rate [Member] Valuation Approach and Technique [Axis] Valuation Technique, Discounted Cash Flow [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Measurement Input, EBITDA Multiple [Member] Measurement Input Weighted Average Cost Of Capital [Member] Terminal Growth Rate [Member] Product Penetration Rates [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Share Price [Member] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Merger Agreement [Member] Business Combination [Axis] PointR [Member] Statements of Income Location Balance [Axis] In Process Research and Development [Member] Short-Term Debt, Type [Axis] 10% Convertible Note Payable, Due April 23, 2022 - Bridge Investor [Member] Debt Instrument [Axis] Convertible Debentures [Member] 10% Convertible Note Payable, Due April 23, 2022 - Related Party [Member] 10% Convertible Note payable, Due August 6, 2022 - Bridge Investor [Member] 5% Convertible Note Payable - Stephen Boesch [Member] Fall 2019 Notes [Member] 5% Convertible Note Payable - Related Party [Member] 5% Convertible Note Payable - Dr. Sanjay Jha [Member] 5% Convertible Note Payable - CEO & CFO - Related Parties [Member] 5% Convertible Note Payable - Bridge Investors [Member] 5% Convertible Note - Autotelic Inc - Related Party [Member] August 2021 Convertible Notes [Member] 5% Convertible Note - Bridge Investors [Member] 5% Convertible Note - CFO - Related Party [Member] 16% Convertible Notes - Accredited Investors [Member] March 2022 Notes [Member] 2% Convertible Notes - Forever Prosperity [Member] Debt for Clinical Trials GMP [Member] 16% Convertible Notes - Accredited Investors [Member] May 2022 Note [Member] Accrued And Unpaid Interest [Member] JH Darbie PPM 2 Debt [Member] 10% Convertible Note - Accredited Investor [Member] July 2025 Note [Member] January 2026 Note [Member] 10% Convertible Notes Accredited Investors [Member] Pacific Pier 2026 Note [Member] Short Term Debt - Bridge Investors [Member] Other Debt [Member] Short Term Debt From CFO [Member] Short Term Debt - Autotelic Inc. - Related Party [Member] Short Term Debt From CEO [Member] Short Term Debt Accredited Investor [Member] Long-Term Debt, Type [Axis] JH Darbie PPM-3 Debt [Member] Bridge Investor [Member] Securities Purchase Agreement [Member] Convertible Debt [Member] Fall 2019 Debt Financing [Member] Note Purchase Agreements [Member] Dr. Vuong Trieu [Member] Dr. Sanjay Jha [Member] Chulho Park [Member] Amit Shah [Member] Two Accredited Investors [Member] GMP Note [Member] GMP Note 2 [Member] October Purchase Agreement [Member] Convertible Promissory Note [Member] January Purchase Agreement [Member] Unsecured Convertible Note Purchase Agreements [Member] Golden Mountain Partners LLC [Member] Note Purchase Agreement [Member] Fourth Man LLC [Member] Five Institutional Investors [Member] Placement Agent [Member] Blue Lake [Member] Fourth Man Convertible Note [Member] One Institutional Investors [Member] May 2022 Mast Note [Member] May 2022 [Member] July 2025 Mast Note [Member] Warrant [Member] July 2025 [Member] January 2026 Mast Note [Member] June 2026 Financing Note [Member] Autotelic [Member] CFO [Member] Chief Executive Officer [Member] 5% Convertible Notes - Accredited Investors [Member] August 2021 [Member] 10%t Coupon August 2026 [Member] 10% CouponJanuary 2026 [Member] 12% Coupon June 2026 [Member] Other Short Term Advances [Member] Chief Financial Officer [Member] Chief Executive Officer Related Party [Member] Accredited Investor [Member] GMP Bio [Member] Dragon Overseas [Member] JH Darbie Placement Agreement Two [Member] One Convertible Promissory Note [Member] New Subscription Agreements [Member] JH Darbie PPM 3 Debt [Member] Subscription Agreements Two [Member] JH Darbie Subscription Agreement [Member] Subscription Agreements [Member] Service Agreement [Member] Intangible Asset, Finite-Lived, Class [Axis] Intellectual Property [Member] Ownership [Axis] Class of Stock [Axis] Series B Convertible Preferred Stock [Member] Series B Preferred Stock [Member] Asset Transfer Agreement [Member] Master Service Agreement [Member] Autotelic Inc [Member] Vyoung Trieu [Member] Fall 2019 Note [Member] Series A Convertible Preferred Stock [Member] August 2021 Note [Member] Artius Consulting Agreement [Member] Steven King [Member] Term Sheet Agreement [Member] Pacific Pier [Member] Award Type [Axis] Restricted Stock Awards [Member] Jefferson Capital [Member] Valor Nation [Member] Box Capital Inc [Member] Plan Name [Axis] 2017 Equity Incentive Plan [Member] 2015 and 2005 Equity Incentive Plan [Member] Exercise Price Range [Axis] Exercise Price 1 [Member] Exercise Price 2 [Member] Exercise Price 3 [Member] Exercise Price 4 [Member] Exercise Price Five [Member] Restricted Stock Units (RSUs) [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Special Purchase Agreements [Member] Vuong Trieu PhD [Member] Anthony EMaidaIII PhD MAMBA [Member] Steven WKing [Member] Seymour Fein MD [Member] Saran Saund [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] ASSETS Current assets: Cash Restricted cash Accounts receivable Prepaid and other current assets Total current assets In process R&D Goodwill, net of impairment Investment in equity securities Investment in GMP Bio at fair value Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable and accrued liabilities Accounts payable to related party Contingent consideration Derivative liability on notes Convertible debt and short-term debt, net of costs Total current liabilities Convertible long-term debt, net of costs Deferred income tax liability Total liabilities Commitments and contingencies (Note 15) Stockholders’ equity: Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized; 50,900 and 24,388 issued and outstanding, respectively Common stock, $0.01 par value; 750,000,000 shares authorized; 457,012,796 and 442,596,856 issued and outstanding, respectively Additional paid-in capital Accumulated equity Total Oncotelic Therapeutics, Inc. stockholders’ equity Non-controlling interests Total stockholders’ equity Total liabilities and stockholders’ equity Statement of Financial Position [Abstract] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Service revenue Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Other income (expense): Gain on derecognition of non-financial asset Change in fair value equity investment Interest expense, net Change in fair value of derivative on debt Total other income Net income (loss) before non-controlling interests Net loss attributable to non-controlling interests Net income (loss) attributable to Oncotelic Therapeutics, Inc. Basic and diluted net income (loss) per share attributable to common stock Basic and diluted weighted average common stock outstanding Diluted net income (loss) per share attributable to common stock Diluted weighted average common stock outstanding Statement [Table] Statement [Line Items] Balance Balance, shares Preferred shares issued for services Preferred shares issued for services, shares Common shares issued with debt Shares issued in connection with debt and debt conversion, shares Net Income (Loss) Common shares issued upon partial conversion of debt Common shares issued upon partial conversion of debt, shares Shares issued in connection with equity purchase agreement Shares issued in connection with sale of equity, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Amortization of debt discount and deferred finance costs Stock-based compensation Gain on derecognition of non-financial asset Change in fair value equity investment Common shares issued to investors Change in fair value of derivative Changes in operating assets and liabilities: Accounts receivable Prepaids and other current assets Accounts payable and accrued liabilities Accounts payable to related party Net cash used in operating activities Cash flows from financing activities: Proceeds from sales of common stock under equity purchase agreement Net proceeds from convertible debt Proceeds from short term loans, others Repaid to related party/others Net cash provided by financing activities Net increase in cash Cash and restricted cash - beginning of period Cash and restricted cash - end of period Supplemental cash flow information: Cash paid for: Interest paid Non-cash investing and financing activities: Common stock issued in connection with debt Common shares issued upon conversion of debt Equity investment in exchange for non-financial asset Accounting Policies [Abstract] DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Acquisitions Goodwill And Intangible Assets ACQUISITIONS, GOODWILL AND INTANGIBLE ASSETS Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Debt Disclosure [Abstract] CONVERTIBLE DEBENTURES, NOTES AND OTHER DEBT Equity Method Investments and Joint Ventures [Abstract] JOINT VENTURE WITH GMP BIO AND AFFILIATES, EQUITY METHOD INVESTMENT Private Placement -2 Ppm-2 And Jh Darbie Funding PRIVATE PLACEMENT -2 (PPM-2) AND JH DARBIE FUNDING Private Placement -3 Ppm-3 And Jh Darbie Funding PRIVATE PLACEMENT -3 (“PPM-3”) AND JH DARBIE FUNDING Lunai Bioworks Transactions LUNAI BIOWORKS TRANSACTIONS Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Equity Purchase Agreement And Registration Rights Agreement EQUITY PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (MAST HILL) Equity [Abstract] STOCKHOLDERS’ EQUITY PREFERRED STOCK Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Use of Estimates Cash and Restricted Cash Debt issuance Costs and Debt discount Fair Value of Financial Instruments Investment in equity securities Change in Fair Value of Equity Securities of GMP Bio Derivative Liability Related to 2019 Bridge Financing Net Income (Loss) Per Share Stock-Based Compensation Impairment of Long-Lived Assets Intangible Assets Goodwill Derivative Financial Instruments Indexed to the Company’s Common Stock Convertible Instruments Variable Interest Entity (VIE) Accounting Investments - Equity Method Joint Venture agreement Revenue Recognition Research & Development Costs Recent Accounting Pronouncements SCHEDULE OF UNREALIZED GAINS AND LOSSES SCHEDULE OF FAIR VALUE OF INVESTMENT HIERARCHY SCHEDULE OF QUANTITATIVE INFORMATION ABOUT SIGNIFICANT UNOBSERVABLE INPUTS SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES SCHEDULE OF GOODWILL SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES SCHEDULE OF CONVERTIBLE DEBENTURES AND NOTES, NET OF DISCOUNT SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT SCHEDULE OF NET OF DEBT DISCOUNT SCHEDULE OF SHORT-TERM LOANS SCHEDULE OF CHANGE IN FAIR VALUE OF OUR INVESTMENT Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT SCHEDULE OF FAIR VALUE WARRANTS SCHEDULE OF DEBT RECORDED UNDER THE SUBSCRIPTION AGREEMENT SCHEDULE OF PREFERRED STOCK SCHEDULE OF COMPENSATION BASED STOCK OPTION ACTIVITY SCHEDULE OF OPTIONS TO PURCHASE SHARES OF COMMON STOCK OUTSTANDING AND EXERCISABLE SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE SCHEDULE OF RSU AWARDS Nature of Operation, Product Information, Concentration of Risk [Table] Ownership interest Development costs Debt instrument face amount Maximum commitment amount Shares of common stock Cash proceeds Sale of common stock Market capitalization Stockholders equity other Debt conversion amount Debt conversion, description Conversion fee, shares Net income loss Net loss Increase in fair value ownership Deferred taxes Working capital deficit Cash flows from operations Proceeds from Convertible Debt ScheduleOfSignificantAccountingPoliciesTable [Table] Cash equivalents Initial fair value Gain loss on fair value of investement Joint venture combined enterprise value Fair value of investment in joint venture Joint venture other participant capital contribution Carrying value of investment Discount rate Fair value investment net Proceeds from convertible loan Discount rate limitations Investment fair value Gain on investments Contigent consideration Common stock equivalents shares Weighted average common stock Impairment losses for long- lived assets Impairment of intangible assets Variable interest entity percentage Net assets Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Investment in equity securities, beginning period fair value Adjustment to Fair Value Investment in equity securities, ending period fair value Fair value of equity investment Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Line Items] Fair value unobservable inputs, percentage rate Balance at January 1, 2026 and 2025 Change in fair value Balance at June 30, 2026 and December 31, 2025 Derivative liability measurement input Life of instrument in years Schedule Of Goodwill Balance at January 1, 2026 and 2025 Less: Goodwill impairment due to market capitalization Balance at June 30, 2026 and December 31, 2025 Goodwill Derecognized goodwill Asset impairment charges Impairment charge Intangible asset, net Accounts payable Accrued liabilities Total accounts payable and accrued liabilities Accounts payable – related party Short-Term Debt [Table] Short-Term Debt [Line Items] Convertible Note payable Short term debt Total convertible debt and short-term debt – related party, net Total May 2022 convertible note, net Unamortized debt discount Pacific Pier Convertible note, inclusive of accrued interest 12% coupon, gross Less Debt discount recorded Amortization debt discount Total Pacific Pier 2016 convertible note, net Short term advance  Derivative liability Credit risk derivative liabilities, at fair value Principal amount Debt Financing Gross proceeds Additional funding to related party Debt interest rate Debt unamortized principal amount Interest expense, debt Convertible Debt Accrued interest Convertible notes payable Proceeds from issuance of common stock Debt conversion description Conversion price Interest expense Debt instrument interest rate effective percentage Granted total number of warrants Share price Granted Amount of debt converted Convertible notes into common stock, shares Debt default principal and accrued interest percentage Estimated default penalty Issuance of common stock Accrued interest Conversion fee, shares Accrued interest Interest expense, debt, excluding amortization Related party debt Repayments of short term debt Short term debt, average outstanding amount Proceeds from related party Short-term loan Balance at beginning of period Change in fair value of investment Balance at end of period Equity Method Investment [Table] Schedule of Equity Method Investments [Line Items] Ownership percentage Intangible assets net excluding goodwill Fair value of equity Assets Liabilities Loans received Operating expenses Investment owned PrivatePlacementAndJhDarbieFundingTable [Table] Sale of transaction shares Converted debt Percentage of convertible unsecured promissory note Shares and warrants issued in connection with debt, shares Number of common stock issued Shares issued price per share Extinguishment of debt amount Amortization of debt Debt discount and issuance costs Accrued, returned and unpaid interest Total PPM-2 Darbie Financing, net of discounts Business Combination [Table] Business Combination [Line Items] Warrant expected term Warrants measurement input Number of common stock value Professional fees Debt instrument fee amount Debt conversion description Debt instrument repaid Issuance cost Stock issued during the period warrant grant Debt extinguishment Share based compensation arrangements, grants Additional paid in capital Debt discount Total convertible promissory, net of discounts LunaiBioworksTransactionsTable [Table] Share based compensation Account payable related party Provisional patents amount Account payable Revenue Ownership percentage Minority interest percentage Shares issued Limited Liability Company (LLC) Preferred Unit, Issuance Value Gain in the value Related Party Transaction [Table] Related party expenses Debt instrument unamortized discount Debt conversion Other liabilities, current Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Conversion of Stock, Shares Converted Stock Issued During Period, Shares, Restricted Stock Award, Gross Shares issued upon conversion Term sheet payment advanced EquityPurchaseAgreementAndRegistrationRightsAgreementTable [Table] Warrants issued to purchase common stock Value of shares available for purchase Share puchase description Deferred finance cost Shares issued in connection with sale of equity Common stock, par value Non cash issuance costs Stock, Class of Stock [Table] Legal fees Debt conversion shares Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Issuance of preferred stock, shares Issuance of preferred stock Class of Stock [Line Items] Restricted stock grant Preferred stock, convertible, shares issuable Conversion of stock, shares converted Trading preferred stock shares Grant date fair value Stock based compensation Unamortized expense Deferred compensation expenses Unamortized debt issuance expense Options outstanding, Balance Weighted average exercise price outstanding, Balance Options outstanding, expired or cancelled Weighted average exercise price outstanding, expired or cancelled Options outstanding, Balance Weighted average exercise price outstanding, Balance Options exercisable, Balance Weighted average exercise price options exercisable Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise prices, Lower limit Exercise prices, Upper limit Number of Outstanding Options Weighted Average Remaining Life In Years Weighted-Average Exercise Price Number of Exercisable Options Number of Stock Options Outstanding, Balance Weighted-Average Exercise Price, Outstanding, beginning balance Number of Stock Options, Issued Weighted-Average Exercise Price, Issued Number of Stock Options, Expired / cancelled Weighted-Average Exercise Price, Expired / cancelled Number of Stock Options Outstanding, Balance Weighted-average exercise price, outstanding, Balance Warrants Outstanding, Exercise Price Warrants, Number Outstanding Weighted Average Remaining Life in Years Warrants Weighted Average Exercise Price Warrants Outstanding, Number Exercisable Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Compensation for services, shares Compensation for services, amount Stock compensation expense Share based compensation Number of common stock authorized for issuance Options exercisable period Options vesting period Unamortized stock compensation cost Unvested stock options description Purchase price Contingent consideration of shares issuable Subsequent Event [Table] Restricted stock unit award Preferred Stock convertible Debt instrument, description Subsequent Event [Line Items] Number of RSUs granted JV [Member] GMP Bio [Member] Dragon Overseas [Member] Golden Mountain Partners [Member] GMP Biotechnology Limited [Member] Private Placement Two and Financing Disclosure [Text Block] JH Darbie Placement Agreement [Member] Accredited Investors [Member] JH Darbie Placement Agreement Two [Member] One Convertible Promissory Note [Member] JH Darbie PPM 2 Debt [Member] New Subscription Agreements [Member] JH Darbie PPM 3 Debt [Member] Schedule of Funds Received Under The Subscription Agreement From The Private Placement Net of Debt [Discount Table Text Block] Private Placement Three And Financing Disclosure [Text Block] JH Darbie Subscription Agreement [Member] Subscription Agreements [Member] Schedule Of Debt Recorded Under The Subscription Agreemen Debt Discount [Table Text Block] Stock issued during period shares warrants granted. Shares issued value in connection with sale of equity. shares issued shares in connection with sale of equity Gain on derecognition of non financial asset. Gain on derecognition of non financial asset and change in value of equity securities. Service Agreement [Member] Lunai Bioworks, Inc [Member] Provisional patents amount. Merger Agreement [Member] Series B Convertible Preferred Stock [Member] Asset Transfer Agreement [Member] Common shares issued upon conversion of debt. Master Service Agreement [Member] Autotelic Inc [Member] Vyoung Trieu [Member] Securities Purchase Agreement [Member] Fall 2019 Note [Member] Series A Convertible Preferred Stock [Member] August 2021 Note [Member] Steven King [Member] Term Sheet Agreement [Member] Equity Purchase Agreement And Registration Rights Agreement Mas Hill [Text Block] Equity Purchase Agreement [Member] Securities Purchase Agreements [Member] July 2025 Mast Note [Member] Market capitalization Independent Contractor Agreement [Member] Fourth Man LLC [Member] Securities Purchase Agreement and Purchase Agreement [Member] Since Inception Date [Member] Point R merger agreement [Member] Working capital deficit. Mast Hill [Member] Pacific Pier [Member] Debt Issuance Costs And Debt Discount [Policy Text Block] Dr Vuong Trieu [Member] Restricted Stock Awards [Member] Employee service share based compensation unamortized compensation cost. Jefferson Capital [Member] Valor Nation [Member] Box Capital Inc [Member] 2017 Equity Incentive Plan [Member] 2015 and 2005 Equity Incentive Plan [Member] Exercise Price 1 [Member] Exercise Price 2 [Member] Exercise Price 3 [Member] Schedule of Unrealized Loss on Investment [Table Text Block] Weighted-average exercise price, outstanding. Weighted-average exercise price, issued. Weighted-average exercise price, expired or cancelled. Change in Fair Value of Equity Securities [Policy Text Block] Joint venture combined enterprise value. Joint venture other participant capital contribution. Schedule of Warrants Outstanding and Exercisable [Table Text Block] Fair value unobservable inputs percentage rate. Measurement Input Revenue Growth Rate [Member] Measurement Input Weighted Average Cost Of Capital [Member] Terminal Growth Rate [Member] Product Penetration Rates [Member] Exercise Price 4 [Member] Fair value net investment. Exercise Price Five [Member] Warrants weighted- average exercise price of warrants. Point R Merger [Member] Lunai [Member] Lunai Bioworks [Disclosure Text Block] Derivatives Liability [Policy Text Block] Summary of Changes in Fair Value of Derivative Liabilities [Table Text Block] Derivative liability, measurement input term. PointR [Member] Joint Venture Agreement [Policy Text Block] Acquisitions Goodwill And Intangible Assets [Text Block] Statements of Income Location Balance [Axis] 10% Convertible Notes Accredited Investors [Member] January 2026 Note [Member] Bridge Investor [Member] Convertible Debentures [Member] Fall 2019 Debt Financing [Member] Debt financing. Note Purchase Agreements [Member] Fall 2019 Notes [Member] Gross proceeds from convertible debt. Dr Sanjay Jha [Member] Chulho Park [Member] Amit Shah [Member] Two Accredited Investors [Member] Debt unamortized principal amount. GMP Note [Member] GMP Note 2 [Member] October Purchase Agreement [Member] Convertible Promissory Note [Member] January Purchase Agreement [Member] Unsecured Convertible Note Purchase Agreements [Member] Golden Mountain Partners LLC [Member]. Note Purchase Agreement [Member] Schedule of Convertible Notes, Net of Discount [Table Text Block] August 2021 [Member] Five Institutional Investors [Member] Placement Agent [Member] Vuong Trieu PhD [Member] Anthony EMaidaIII PhD MAMBA [Member] Debt default principal and accrued interest percentage. Blue Lake [Member] Estimated default penalty. Steven WKing [Member] Fourth Man Convertible Note [Member] One Institutional Investors [Member] Seymour Fein MD [Member] Saran Saund [Member] May 2022 [Member] Amortization of debt discount. Convertible notes payable net. July 2025 [Member] January Two Thousand and Twenty Six Mast Note [Member] June 2026 Financing Note [Member] Other Short Term Advances [Member] Autotelic [Member] CFO [Member] May 2022 Mast Note [Member] Investment fair value. Dragon Overseas Capital Limited [Member] May 2022 Note and July 2025 Note [Member] May 2022 Note [Member] Artius Consulting Agreement [Member] Special Purchase Agreements [Member] Fair value inputs discount rate. 10% Convertible Note Payable, Due April 23, 2022 - Bridge Investor [Member] 10% Convertible Note Payable, Due April 23, 2022 - Related Party [Member] 10% Convertible Note payable, Due August 6, 2022 - Bridge Investor [Member] Accrued And Unpaid Interest [Member] Pacific Pier 2026 Note [Member] 5% Convertible Note Payable - Stephen Boesch [Member] 5% Convertible Note Payable - Related Party [Member] 5% Convertible Note Payable - Dr. Sanjay Jha [Member] 5% Convertible Note Payable - CEO & CFO - Related Parties [Member] 5% Convertible Note Payable - Bridge Investors [Member] 5% Convertible Note - Autotelic Inc - Related Party [Member] August 2021 Convertible Notes [Member] 5% Convertible Note - Bridge Investors [Member] 5% Convertible Note - CFO - Related Party [Member] 16% Convertible Notes - Accredited Investors [Member] March 2022 Notes [Member] 2% Convertible Notes - Forever Prosperity [Member] Debt for Clinical Trials GMP [Member] 16% Convertible Notes - Accredited Investors [Member] May 2022 Note [Member] 10% Convertible Note - Accredited Investor [Member] July 2025 Note [Member] Short Term Debt - Bridge Investors [Member] Other Debt [Member] Short Term Debt From CFO [Member] Short Term Debt - Autotelic Inc. - Related Party [Member] Short Term Debt From CEO [Member] Short Term Debt Accredited Investor [Member] JH Darbie PPM-3 Debt [Member] 5% Convertible Notes - Accredited Investors [Member] Fair value inputs discount rate limitations. 10%t Coupon August 2026 [Member] 10% CouponJanuary 2026 [Member] Subscription Agreements Two [Member] Chief Executive Officer Related Party [Member] Accredited Investor [Member] 12% Coupon June 2026 [Member] Weighted average common stock. Common stock issued in connection with debt. Change in fair value equity investment. 16% Convertible Notes - Accredited Investors [Member] [Default Label] May 2022 Note [Member] [Default Label] Assets, Current Liabilities, Current Equity, Attributable to Parent Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Income (Loss) Interest Expense, Nonoperating Nonoperating Income (Expense) Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Payable, Related Parties Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Investment, Policy [Policy Text Block] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Accounts Payable and Accrued Liabilities Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Interest Payable Debt Instrument, Increase, Accrued Interest Investments, Fair Value Disclosure Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Weighted-average exercise price, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations